T-bet抑制慢性淋巴细胞白血病中恶性B细胞的增殖
该研究对慢性淋巴细胞白血病(CLL)患者的恶性B细胞进行单细胞多组学分析,并研究Tbx21基因敲除的CLL小鼠模型。发现T-bet通过降低增殖速率发挥肿瘤抑制因子作用,NF-κB活性诱导T-bet表达,T-bet主要抑制转录调控特定基因特征,与患者更长总生存期相关。
要点
- T-bet在恶性B细胞中作为肿瘤抑制因子,降低其增殖速率。
- 微环境炎症信号诱导的NF-κB活性触发T-bet表达,T-bet主要抑制转录。
- T-bet抑制细胞周期,并与CLL患者更长总生存期相关。
核心结论
- T-bet通过调控炎症过程和细胞周期在恶性B细胞中发挥肿瘤抑制作用。
- 将T-bet活性与炎症关联可解释CLL中炎症信号通路遗传改变的良性预后作用。
研究设计与样本
- 对CLL患者的恶性B细胞进行单细胞分辨率多组学分析。
- 研究Tbx21基因敲除的CLL小鼠模型。
主要发现
- T-bet作为肿瘤抑制因子降低恶性B细胞增殖速率。
- NF-κB活性触发T-bet表达,影响启动子近端和远端染色质共可及性,主要通过抑制转录控制特定基因特征。
- 基因集富集分析显示T-bet正向调控干扰素信号、负向控制增殖。
- T-bet抑制细胞周期,并与CLL患者更长总生存期相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The T-box transcription factor T-bet is known as a master regulator of the T-cell response but its role in malignant B cells has not been sufficiently explored. Here, we conducted single-cell resolved multi-omics analyses of malignant B cells from patients with chronic lymphocytic leukemia (CLL) and studied a CLL mouse model with a genetic knockout of Tbx21. We found that T-bet acts as a tumor suppressor in malignant B cells by decreasing their proliferation rate. NF-κB activity, induced by inflammatory signals provided by the microenvironment, triggered T-bet expression, which affected promoter-proximal and distal chromatin coaccessibility and controlled a specific gene signature by mainly suppressing transcription. Gene set enrichment analysis identified a positive regulation of interferon signaling and negative control of proliferation by T-bet. In line, we showed that T-bet represses cell cycling and is associated with longer overall survival of patients with CLL. Our study uncovered a novel tumor suppressive role of T-bet in malignant B cells via its regulation of inflammatory processes and cell cycling, which has implications for the stratification and therapy of patients with CLL. Linking T-bet activity to inflammation explains the good prognostic role of genetic alterations in the inflammatory signaling pathways in CLL.
引用
- Roessner PM, Seufert I, Chapaprieta V, et al. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia. Blood. 2024. PMID: 38684038. doi:10.1182/blood.2023021990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。